[FWP] Inverse VIX Short-Term Futures ETNs due March 22, 2045 Free Writing Prospectus
Form 4 Overview: Maravai LifeSciences Holdings, Inc. (MRVI) disclosed that director John A. DeFord acquired 89,139 shares of Class A common stock on 16 June 2025.
Transaction details: The shares were granted as restricted stock units (RSUs) under the company’s 2020 Omnibus Incentive Plan at an assigned value of $2.16 per share. These RSUs will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual shareholder meeting.
Post-transaction ownership: Following the award, DeFord’s beneficial ownership rises to 159,185 shares, all held directly.
Implications: A director increasing his stake—albeit via equity compensation—tends to align management and shareholder interests and can be interpreted as a vote of confidence in MRVI’s long-term prospects. Because the grant stems from an incentive plan rather than an open-market purchase, any cash outlay by the insider is not indicated in the filing.
Panoramica del Modulo 4: Maravai LifeSciences Holdings, Inc. (MRVI) ha comunicato che il direttore John A. DeFord ha acquisito 89.139 azioni di azioni ordinarie di Classe A il 16 giugno 2025.
Dettagli della transazione: Le azioni sono state assegnate come unità azionarie vincolate (RSU) nell'ambito del Piano Incentivi Omnibus 2020 della società, con un valore attribuito di 2,16 dollari per azione. Queste RSU matureranno completamente al verificarsi del primo tra (i) un anno dalla data di assegnazione o (ii) la data dell'assemblea annuale degli azionisti del 2026.
Proprietà dopo la transazione: Dopo l'assegnazione, la proprietà effettiva di DeFord sale a 159.185 azioni, tutte detenute direttamente.
Implicazioni: L'aumento della partecipazione da parte di un direttore — anche se tramite compensi azionari — tende ad allineare gli interessi della direzione con quelli degli azionisti e può essere interpretato come un segnale di fiducia nelle prospettive a lungo termine di MRVI. Poiché l'assegnazione deriva da un piano di incentivi e non da un acquisto sul mercato aperto, non è indicata alcuna uscita di denaro da parte dell'insider nel documento.
Resumen del Formulario 4: Maravai LifeSciences Holdings, Inc. (MRVI) informó que el director John A. DeFord adquirió 89,139 acciones ordinarias Clase A el 16 de junio de 2025.
Detalles de la transacción: Las acciones fueron otorgadas como unidades restringidas de acciones (RSUs) bajo el Plan de Incentivos Omnibus 2020 de la empresa, con un valor asignado de 2.16 dólares por acción. Estas RSUs se consolidarán por completo al ocurrir lo primero entre (i) un año desde la fecha de concesión o (ii) la fecha de la reunión anual de accionistas de 2026.
Propiedad tras la transacción: Tras la adjudicación, la propiedad efectiva de DeFord aumenta a 159,185 acciones, todas en propiedad directa.
Implicaciones: Que un director aumente su participación —aunque sea mediante compensación accionaria— suele alinear los intereses de la gerencia y los accionistas y puede interpretarse como una señal de confianza en las perspectivas a largo plazo de MRVI. Dado que la concesión proviene de un plan de incentivos y no de una compra en el mercado abierto, no se indica desembolso en efectivo por parte del insider en el informe.
폼 4 개요: Maravai LifeSciences Holdings, Inc. (MRVI)는 이사 John A. DeFord가 2025년 6월 16일에 클래스 A 보통주 89,139주를 취득했다고 공시했습니다.
거래 세부사항: 해당 주식은 회사의 2020년 종합 인센티브 플랜에 따라 제한 주식 단위(RSU)로 부여되었으며, 주당 평가 가치는 2.16달러입니다. 이 RSU는 부여일로부터 1년이 경과하거나 2026년 연례 주주총회 날짜 중 빠른 시점에 전부 취득됩니다.
거래 후 소유 현황: 부여 후 DeFord의 실질 소유 주식 수는 159,185주로 증가했으며, 모두 직접 보유 중입니다.
의미: 이사가 지분을 늘리는 것은—비록 주식 보상 방식을 통해서지만—경영진과 주주의 이해관계를 일치시키는 경향이 있으며 MRVI의 장기 전망에 대한 신뢰의 표시로 해석될 수 있습니다. 이 부여는 공개 시장에서의 매입이 아닌 인센티브 플랜에 따른 것이므로 내부자의 현금 지출은 공시서류에 나타나지 않습니다.
Vue d'ensemble du formulaire 4 : Maravai LifeSciences Holdings, Inc. (MRVI) a révélé que le directeur John A. DeFord a acquis 89 139 actions ordinaires de classe A le 16 juin 2025.
Détails de la transaction : Les actions ont été attribuées sous forme d'unités d'actions restreintes (RSU) dans le cadre du Plan d'incitation omnibus 2020 de la société, à une valeur assignée de 2,16 $ par action. Ces RSU seront entièrement acquises au plus tôt entre (i) un an à compter de la date d'attribution ou (ii) la date de l'assemblée annuelle des actionnaires de 2026.
Propriété après la transaction : Après cette attribution, la détention effective de DeFord s'élève à 159 185 actions, toutes détenues directement.
Implications : Qu'un directeur augmente sa participation — même via une rémunération en actions — tend à aligner les intérêts de la direction avec ceux des actionnaires et peut être interprété comme un signe de confiance dans les perspectives à long terme de MRVI. Étant donné que cette attribution provient d'un plan d'incitation et non d'un achat sur le marché libre, aucune sortie de trésorerie de la part de l'initié n'est indiquée dans le dépôt.
Überblick Formular 4: Maravai LifeSciences Holdings, Inc. (MRVI) gab bekannt, dass Direktor John A. DeFord am 16. Juni 2025 89.139 Aktien der Klasse A Stammaktien erworben hat.
Transaktionsdetails: Die Aktien wurden als Restricted Stock Units (RSUs) im Rahmen des Omnibus-Incentive-Plans 2020 des Unternehmens zu einem zugewiesenen Wert von 2,16 USD pro Aktie gewährt. Diese RSUs werden vollständig ausgeübt, je nachdem, was früher eintritt: (i) ein Jahr nach dem Gewährungsdatum oder (ii) dem Datum der Jahreshauptversammlung 2026.
Besitz nach der Transaktion: Nach der Zuteilung steigt DeFords wirtschaftliches Eigentum auf 159.185 Aktien, die alle direkt gehalten werden.
Auswirkungen: Wenn ein Direktor seinen Anteil erhöht – auch wenn dies durch Aktienvergütung geschieht – neigt dies dazu, die Interessen des Managements mit denen der Aktionäre in Einklang zu bringen und kann als Vertrauensbeweis in die langfristigen Aussichten von MRVI interpretiert werden. Da die Zuteilung aus einem Anreizplan stammt und nicht aus einem Kauf am offenen Markt, ist im Bericht kein Barausgang des Insiders angegeben.
- Director ownership increases by 89,139 shares, raising total holdings to 159,185 and enhancing alignment with shareholders.
- Equity award vests within one year, encouraging near-term board engagement and retention.
- None.
Insights
TL;DR: Director received 89k RSUs, boosting stake to 159k shares; signals alignment but no cash purchase.
From a capital-markets standpoint, DeFord’s RSU grant modestly increases insider ownership, which many investors view as a governance positive. The transaction adds ~0.07% to MRVI’s 135 million share count—immaterial for dilution—but confirms ongoing use of equity incentives to attract and retain leadership. Given the $2.16 reference price, the award value is roughly $192k, a small expense relative to MRVI’s market cap. Because the filing shows a code "A" rather than "P," the acquisition is not an open-market buy and therefore carries less immediate signaling power. Overall impact: mildly constructive.
TL;DR: Fresh RSU grant under 2020 Plan ties director compensation to performance; limited dilution, neutral financial impact.
The one-year/next-AGM vesting schedule promotes short-term board retention while still aligning incentives with shareholder returns through equity-based pay. No indicators of insider selling or material governance concerns are present. As the award is routine under an approved plan, it is unlikely to shift voting dynamics or trigger proxy advisory scrutiny.
Panoramica del Modulo 4: Maravai LifeSciences Holdings, Inc. (MRVI) ha comunicato che il direttore John A. DeFord ha acquisito 89.139 azioni di azioni ordinarie di Classe A il 16 giugno 2025.
Dettagli della transazione: Le azioni sono state assegnate come unità azionarie vincolate (RSU) nell'ambito del Piano Incentivi Omnibus 2020 della società, con un valore attribuito di 2,16 dollari per azione. Queste RSU matureranno completamente al verificarsi del primo tra (i) un anno dalla data di assegnazione o (ii) la data dell'assemblea annuale degli azionisti del 2026.
Proprietà dopo la transazione: Dopo l'assegnazione, la proprietà effettiva di DeFord sale a 159.185 azioni, tutte detenute direttamente.
Implicazioni: L'aumento della partecipazione da parte di un direttore — anche se tramite compensi azionari — tende ad allineare gli interessi della direzione con quelli degli azionisti e può essere interpretato come un segnale di fiducia nelle prospettive a lungo termine di MRVI. Poiché l'assegnazione deriva da un piano di incentivi e non da un acquisto sul mercato aperto, non è indicata alcuna uscita di denaro da parte dell'insider nel documento.
Resumen del Formulario 4: Maravai LifeSciences Holdings, Inc. (MRVI) informó que el director John A. DeFord adquirió 89,139 acciones ordinarias Clase A el 16 de junio de 2025.
Detalles de la transacción: Las acciones fueron otorgadas como unidades restringidas de acciones (RSUs) bajo el Plan de Incentivos Omnibus 2020 de la empresa, con un valor asignado de 2.16 dólares por acción. Estas RSUs se consolidarán por completo al ocurrir lo primero entre (i) un año desde la fecha de concesión o (ii) la fecha de la reunión anual de accionistas de 2026.
Propiedad tras la transacción: Tras la adjudicación, la propiedad efectiva de DeFord aumenta a 159,185 acciones, todas en propiedad directa.
Implicaciones: Que un director aumente su participación —aunque sea mediante compensación accionaria— suele alinear los intereses de la gerencia y los accionistas y puede interpretarse como una señal de confianza en las perspectivas a largo plazo de MRVI. Dado que la concesión proviene de un plan de incentivos y no de una compra en el mercado abierto, no se indica desembolso en efectivo por parte del insider en el informe.
폼 4 개요: Maravai LifeSciences Holdings, Inc. (MRVI)는 이사 John A. DeFord가 2025년 6월 16일에 클래스 A 보통주 89,139주를 취득했다고 공시했습니다.
거래 세부사항: 해당 주식은 회사의 2020년 종합 인센티브 플랜에 따라 제한 주식 단위(RSU)로 부여되었으며, 주당 평가 가치는 2.16달러입니다. 이 RSU는 부여일로부터 1년이 경과하거나 2026년 연례 주주총회 날짜 중 빠른 시점에 전부 취득됩니다.
거래 후 소유 현황: 부여 후 DeFord의 실질 소유 주식 수는 159,185주로 증가했으며, 모두 직접 보유 중입니다.
의미: 이사가 지분을 늘리는 것은—비록 주식 보상 방식을 통해서지만—경영진과 주주의 이해관계를 일치시키는 경향이 있으며 MRVI의 장기 전망에 대한 신뢰의 표시로 해석될 수 있습니다. 이 부여는 공개 시장에서의 매입이 아닌 인센티브 플랜에 따른 것이므로 내부자의 현금 지출은 공시서류에 나타나지 않습니다.
Vue d'ensemble du formulaire 4 : Maravai LifeSciences Holdings, Inc. (MRVI) a révélé que le directeur John A. DeFord a acquis 89 139 actions ordinaires de classe A le 16 juin 2025.
Détails de la transaction : Les actions ont été attribuées sous forme d'unités d'actions restreintes (RSU) dans le cadre du Plan d'incitation omnibus 2020 de la société, à une valeur assignée de 2,16 $ par action. Ces RSU seront entièrement acquises au plus tôt entre (i) un an à compter de la date d'attribution ou (ii) la date de l'assemblée annuelle des actionnaires de 2026.
Propriété après la transaction : Après cette attribution, la détention effective de DeFord s'élève à 159 185 actions, toutes détenues directement.
Implications : Qu'un directeur augmente sa participation — même via une rémunération en actions — tend à aligner les intérêts de la direction avec ceux des actionnaires et peut être interprété comme un signe de confiance dans les perspectives à long terme de MRVI. Étant donné que cette attribution provient d'un plan d'incitation et non d'un achat sur le marché libre, aucune sortie de trésorerie de la part de l'initié n'est indiquée dans le dépôt.
Überblick Formular 4: Maravai LifeSciences Holdings, Inc. (MRVI) gab bekannt, dass Direktor John A. DeFord am 16. Juni 2025 89.139 Aktien der Klasse A Stammaktien erworben hat.
Transaktionsdetails: Die Aktien wurden als Restricted Stock Units (RSUs) im Rahmen des Omnibus-Incentive-Plans 2020 des Unternehmens zu einem zugewiesenen Wert von 2,16 USD pro Aktie gewährt. Diese RSUs werden vollständig ausgeübt, je nachdem, was früher eintritt: (i) ein Jahr nach dem Gewährungsdatum oder (ii) dem Datum der Jahreshauptversammlung 2026.
Besitz nach der Transaktion: Nach der Zuteilung steigt DeFords wirtschaftliches Eigentum auf 159.185 Aktien, die alle direkt gehalten werden.
Auswirkungen: Wenn ein Direktor seinen Anteil erhöht – auch wenn dies durch Aktienvergütung geschieht – neigt dies dazu, die Interessen des Managements mit denen der Aktionäre in Einklang zu bringen und kann als Vertrauensbeweis in die langfristigen Aussichten von MRVI interpretiert werden. Da die Zuteilung aus einem Anreizplan stammt und nicht aus einem Kauf am offenen Markt, ist im Bericht kein Barausgang des Insiders angegeben.
North America Structured Investments 3yr RTY/SPX Auto Callable Buffered Return Enhanced Notes The following is a summary of the terms of the notes offered by the preliminary pricing supplement hyperlinked below. Summary of Terms J.P. Morgan Structured Investments | 1 800 576 3529 | jpm_structured_investments@jpmorgan.com JPMorgan Chase Financial Company LLC JPMorgan Chase & Co. $1,000 ® ® Russell 2000 Index and S&P 500 Index Issuer: Guarantor: Minimum Denomination: Underlyings: Upside Leverage Factor: Buffer Amount: Pricing Date: Review Date : Observation Date : Maturity Date: CUSIP: Preliminary Pricing Supplement: Estimated Value: 1.25 20.00% July 11, 2025 July 17, 2026 July 11, 2028 July 14, 2028 48136E5X9 http://sp.jpmorgan.com/document/cusip/48136E5X9/doctype/Product_Termsheet/document.pdf The estimated value of the notes, when the terms of the notes are set, will not be less than $940.00 per $1,000 principal amount note. For more information about the estimated value of the notes, which likely will be lower than the price you paid for the notes, please see the hyperlink above. You may lose some or all of your principal at maturity. Any payment on the notes is subject to the credit risk of JPMorgan Chase Financial Company LLC, as issuer of the notes, and the credit risk of JPMorgan Chase & Co., as guarantor of the notes. Automatic Call If the closing value of each Underlying on the Review Date is greater than or equal to its Call Value, the notes will be automatically called for a cash payment, for each $1,000 principal amount note, equal to (a) $1,000 plus (b) the Call Premium Amount, payable on the Call Settlement Date. No further payments will be made on the notes. If the notes are automatically called, you will not benefit from the Upside Leverage Factor that applies to the payment at maturity if the Final Value of each Underlying is greater than its Initial Value. Because the Upside Leverage Factor does not apply to the payment upon an automatic call, the payment upon an automatic call may be significantly less than the payment at maturity for the same level of appreciation in the Lesser Performing Underlying. Call Value Call Premium* 100.00% of the Initial Value At least 10.00% Payment At Maturity If the notes have not been automatically called and the Final Value of each Underlying is greater than its Initial Value, your payment at maturity per $1,000 principal amount note will be calculated as follows: $1,000 + ($1,000 î Lesser Performing Underlying Return î Upside Leverage Factor) If the notes have not been automatically called and (i) the Final Value of one Underlying is greater than its Initial Value and the Final Value of the other Underlying is equal to its Initial Value or is less than its Initial Value by up to the Buffer Amount or (ii) the Final Value of each Underlying is equal to its Initial Value or is less than its Initial Value by up to the Buffer Amount, you will receive the principal amount of your notes at maturity. If the notes have not been automatically called and the Final Value of either Underlying is less than its Initial Value by more than the Buffer Amount, your payment at maturity per $1,000 principal amount note will be calculated as follows: $1,000 + [$1,000 î (Lesser Performing Underlying Return + Buffer Amount)] If the notes have not been automatically called and the Final Value of either Underlying is less than its Initial Value by more than the Buffer Amount, you will lose some or most of your principal amount at maturity. Hypothetical Examples of Amounts Payable Upon Automatic Call or at Maturity** Total Return at Maturity if not Automatically Called Total Return at Review Date* Lesser Performing Underlying Return at Review Date/ Observation Date 81.25% 10.00% 65.00% 62.50% 10.00% 50.00% 50.00% 10.00% 40.00% 25.00% 10.00% 20.00% 12.50% 10.00% 10.00% 6.25% 10.00% 5.00% 0.00% 10.00% 0.00% 0.00% N/A - 0.01% 0.00% N/A - 5.00% 0.00% N/A - 10.00% 0.00% N/A - 20.00% - 0.01% N/A - 20.01% - 10.00% N/A - 30.00% - 20.00% N/A - 40.00% - 40.00% N/A - 60.00% - 60.00% N/A - 80.00% - 80.00% N/A - 100.00% N/A – indicates that the notes would not be called and no payment would be made. * Reflects a Call Premium of 10.00% per annum. The Call Premium will be determined on the Pricing Date and will not be less than 10.00% per annum. ** The hypothetical returns on the notes shown above apply only if you hold the notes for their entire term or until automatically called. These hypotheticals do not reflect fees or expenses that would be associated with any sale in the secondary market. If these fees and expenses were included, the hypothetical returns shown above would likely be lower.
North America Structured Investments 3yr RTY/SPX Auto Callable Buffered Return Enhanced Notes Selected Risks Ɣ Ɣ Your investment in the notes may result in a loss. The notes do not guarantee any return of principal. Any payment on the notes is subject to the credit risks of JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co. Therefore the value of the notes prior to maturity will be subject to changes in the market’s view of the creditworthiness of JPMorgan Chase Financial Company LLC or JPMorgan Chase & Co. If the notes are automatically called, the appreciation potential of the notes is limited to the Call Premium Amount paid on the notes. You are exposed to the risk of decline in the value of each Underlying. Your payment at maturity will be determined by the Lesser Performing Underlying. The automatic call feature may force a potential early exit. No interest payments, dividend payments or voting rights. JPMorgan Chase & Co. is currently one of the companies that make up the S&P 500 ® Index. The notes are subject to the risks associated with small capitalization stocks with respect to the Russell 2000 ® Index. As a finance subsidiary, JPMorgan Chase Financial Company LLC has no independent operations and has limited assets. Ɣ Ɣ Ɣ Ɣ Ɣ Ɣ Ɣ Ɣ Selected Risks (continued) Ɣ Ɣ Ɣ The estimated value of the notes will be lower than the original issue price (price to public) of the notes. The estimated value of the notes is determined by reference to an internal funding rate. The estimated value of the notes does not represent future values and may differ from others’ estimates. The value of the notes, which may be reflected in customer account statements, may be higher than the then - current estimated value of the notes for a limited time period. Lack of liquidity: J.P. Morgan Securities LLC (who we refer to as "JPMS"), intends to offer to purchase the notes in the secondary market but is not required to do so. The price, if any, at which JPMS will be willing to purchase notes from you in the secondary market, if at all, may result in a significant loss of your principal. Potential conflicts: We and our affiliates play a variety of roles in connection with the issuance of notes, including acting as calculation agent and hedging our obligations under the notes, and making the assumptions used to determine the pricing of the notes and the estimated value of the notes when the terms of the notes are set. It is possible that such hedging or other trading activities of J.P. Morgan or its affiliates could result in substantial returns for J.P. Morgan and its affiliates while the value of the notes declines. The tax consequences of the notes may be uncertain. You should consult your tax adviser regarding the U.S. federal income tax consequences of an investment in the notes. Ɣ Ɣ Ɣ Ɣ The risks identified above are not exhaustive. Please see “Risk Factors” in the prospectus supplement and the applicable product supplement, Annex A to the prospectus addendum and “Selected Risk Considerations” in the applicable preliminary pricing supplement for additional information. Additional Information SEC Legend: JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co. have filed a registration statement (including a prospectus) with the SEC for any offerings to which these materials relate. Before you invest, you should read the prospectus in that registration statement and the other documents relating to this offering that JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co. has filed with the SEC for more complete information about JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co. and this offering. You may get these documents without cost by visiting EDGAR on the SEC web site at www.sec.gov. Alternatively, JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co., any agent or any dealer participating in this offering will arrange to send you the prospectus and each prospectus supplement, as well as any product supplement, underlying supplement and preliminary pricing supplement if you so request by calling toll - free 1 - 866 - 535 - 9248. IRS Circular 230 Disclosure: JPMorgan Chase & Co. and its affiliates do not provide tax advice. Accordingly, any discussion of U.S. tax matters contained herein (including any attachments) is not intended or written to be used, and cannot be used, in connection with the promotion, marketing or recommendation by anyone unaffiliated with JPMorgan Chase & Co. of any of the matters addressed herein or for the purpose of avoiding U.S. tax - related penalties. Investment suitability must be determined individually for each investor, and the financial instruments described herein may not be suitable for all investors. This information is not intended to provide and should not be relied upon as providing accounting, legal, regulatory or tax advice. Investors should consult with their own advisers as to these matters. This material is not a product of J.P. Morgan Research Departments. Free Writing Prospectus Filed Pursuant to Rule 433, Registration Statement Nos. 333 - 270004 and 333 - 270004 - 01 J.P. Morgan Structured Investments | 1 800 576 3529 | jpm_structured_investments@jpmorgan.com
FAQ
How many MRVI shares did director John A. DeFord acquire on 16 June 2025?
What is John A. DeFord’s total beneficial ownership in MRVI after the transaction?
When do the newly granted MRVI RSUs vest?
Was the acquisition an open-market purchase?
What was the reference price assigned to the RSUs in the Form 4?
